Build Versus Buy in the Current Biotech Market Environment - How current economic conditions affect your build-or-buy decision. - BioPharm International

ADVERTISEMENT

Build Versus Buy in the Current Biotech Market Environment
How current economic conditions affect your build-or-buy decision.


BioPharm International
Volume 23, Issue 9

ARE CMOS THE ANSWER?

An alternative to building or retrofitting a facility is to partner with a CMO. Indeed, innovator companies have started looking at the strategic benefits of engaging CMOs to support their products throughout their lifecycle: in general, it is likely that the CMO's facility and quality systems already meet regulatory requirements, including international regulations; an innovator company can choose a CMO in a particular location (or locations) as there continues to be significant CMO business development in Singapore, Israel, Japan, and the BRIC countries (Brazil, Russia, India, and China); CMOs are differentiating themselves by increasingly offering specialized technologies and services, and several major CMOs are engaging the innovator companies by exploring alternative business models. In addition, companies have access to CMOs that are already prepared to not only manufacture a myriad of products, but also provide you with technologies and personnel already in place to "hit the ground running" in support of your project needs.

Expression Systems

One of the benefits of working with a CMO is that in some instances the IP holder for a particular expression system is the CMO (for example, G-Pex/Catalent; GS/Lonza; BI-HEX/Boheringer Ingelhiem; CHEF-1/CMC Biologics), or a technology may be available to the CMO (SURE (Selexis), UCOE (Millipore)/Eden Biodesign) and accessing it through the CMO may allow your company to obtain preferential business terms. Discussion of available options that may be most appropriate for the production of your product should be based on your company's supply requirements (current and future); your available budget; any target product delivery date(s); and your company's risk tolerance and regulatory strategy.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

J&J Speeds Ebola Vaccine Development and Expands Production
October 24, 2014
Despite AbbVie Snub, Shire Says it Will Double Sales by 2020
October 24, 2014
Manufacturing Challenges of mAb Production: CHO or Plant Cells?
October 24, 2014
Celgene and Sutro Partner on ADC Development
October 24, 2014
GSK Accelerates Ebola Vaccine Development
October 24, 2014
Author Guidelines
Source: BioPharm International,
Click here